Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.66 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13355955 | 0.91 | CCR1 (0.65) | CCR1LMNAALDH1A1MAPTCXCR3 | |
| SCHEMBL1637827 | 0.90 | CCR1 (0.77) | CCR1TP53 | |
| SCHEMBL1638723 | 0.89 | CCR1 (0.67) | CCR1LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10063573 | 0.88 | CCR1 (0.54) | CCR1CXCR3 | |
| SCHEMBL1637373 | 0.87 | CCR1 (0.64) | CCR1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1638600 | 0.86 | CCR1 (0.81) | CCR1GRM5 | |
| SCHEMBL12726461 | 0.84 | ADAMTS5 (0.46) | CCR1ADAMTS5LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12726456 | 0.84 | CCR1 (0.47) | CCR1ADAMTS5LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13360883 | 0.83 | CCR1 (0.61) | CCR1LMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL15096076 | 0.83 | CCR1 (0.46) | CCR1ADAMTS5LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8481545-B2 | 3-(imidazolyl)-pyrazolo[3,4-b] pyridines | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885ADAMTS5 4630/4885LMNA 4257/4885 |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885ADAMTS5 1171/4885LMNA 4769/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885ADAMTS5 2150/4885LMNA 4347/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885ADAMTS5 2150/4885LMNA 4347/4885 |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885ADAMTS5 4630/4885LMNA 4257/4885 |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885ADAMTS5 1171/4885LMNA 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.